NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that it has commenced a public offering to offer and sell shares of its Common Stock.
All of the shares of Common Stock are being offered by the Company (the “Offering”).
The Company intends to use the net proceeds from the Offering for general corporate and working capital needs. The Company’s Common Stock is trading on the NYSE American LLC under the symbol “DSS”. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
Aegis Capital Corp. is acting as the sole book-running manager for the offering on a firm commitment basis.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-281974) previously filed with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, and declared effective by the SEC on November 5, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About DSS, Inc.
DSS, Inc. is a multinational company operating across multiple business lines including health and wellness, packaging, real estate, and securities and blockchain. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit http://www.dssworld.com.
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
For investor and media inquiries or additional information, please contact:
Investor Contact:
DSS, Inc.
Investor Relations
ir@dssworld.com
+1 (585) 565-2422
